Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1259-1262

  Lindahl, Bengt ^a   Andolf, Ellika ^b   Ingvar, Christian ^a   Ranstam, Jonas ^a   Willén, Roger ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant tamoxifen; Breast cancer; Endometrial carcinoma; Ultrasound

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; ECHOGRAPHY; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PARAMETER; PRIORITY JOURNAL;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 42649102676     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gustafsson J-Å: New insights in oestrogen receptor (ER) research-the ERβ. European J Cancer 74: 245-248, 2000.
2. Gustafsson J-Å, Warner M: Estrogen receptorβ in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochemistry Molecular Biology 74: 245-248, 2000.
3. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N, Askergren J and Hjalmar M-L:Adjuvant tamoxifen in early breast cancer: Occurence of new primary cancers. Lancet 1: 117-120, 1989.
4. Cohen CJ and Rahaman JR: Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy. Cancer Supplement 76: 2044-2052, 1995.
5. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE and Daling JR: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87: 1359-1364, 1995.
6. Early breast Cancer Trialist' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
7. Lindahl B, Andolf E, Ingvar C, Liedman R, Ranstam J and Willen R: Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen. Anticancer Research 17: 3821-3824, 1997.
8. Berlière M, Charles A, Galant C and Donnez J: Uterine side effects of Tamoxifen: A need for systematic pretreatment screening Obstet Gynecol 91: 40-44, 1998.
9. Patriarca MT, de Lima GR, Stavale JN, Goncalves WJ, Freitas V, Soares JM Jr, Simoes MJ and Baracat EC: Ultrasonographic and morphological studies of the postmenopausal endometrium using unopposed estrogen replacement therapy with regular pause: a prospective preliminary study. European J Obstet Gynecol reprod 98: 119-123, 2001.
10. Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J and Cohen I: The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.Gynecol Oncol 94: 754-759, 2004.
11. Garuti G, Cellani F, Centinaio G, Sita G, Nalli G and Luerti M: Histopathologic behaviour of endometrial hyperplasia during tamoxifen therapy for breast cancer. Gynecol oncol 2: 269-273, 2006.
12. Cancerincidence in Sweden 2005. Centre for epidemiology, National Board of Health and Wellfare.2007